BTI
PCVX icon

Blue Trust Inc’s Vaxcyte PCVX Stock Holding History

Blue Trust Inc’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27K Sell
465
-4
-0.9% -$217 ﹤0.01% 1567
2026
Q1 		$27.3K Sell
469
-695
-60% -$37.7K ﹤0.01% 1548
2025
Q4 		$53.7K Sell
1,164
-396
-25% -$17.7K ﹤0.01% 1339
2025
Q3 		$56.2K Sell
1,560
-601
-28% -$19.9K ﹤0.01% 1358
2025
Q2 		$70.3K Buy
2,161
+1,380
+177% +$45.2K ﹤0.01% 1214
2025
Q1 		$29.5K Buy
781
+39
+5% +$3.12K ﹤0.01% 1559
2024
Q4 		$60.7K Buy
742
+371
+100% +$36.8K ﹤0.01% 1161
2024
Q3 		$28K Buy
371
+93
+33% +$8.38K ﹤0.01% 1815
2024
Q2 		$19K Buy
278
+122
+78% +$8.3K ﹤0.01% 1676
2024
Q1 		$10.7K Hold
156
– – ﹤0.01% 1426
2023
Q4 		$8K Hold
156
– – ﹤0.01% 1675
2023
Q3 		$8K Hold
156
– – ﹤0.01% 1487
2023
Q2 		$6K Hold
156
– – ﹤0.01% 1478
2023
Q1 		$7K Hold
156
– – ﹤0.01% 1707
2022
Q4 		$4K Buy
156
+110
+239% +$4.32K ﹤0.01% 1802
2022
Q3 		$1K Buy
+46
New +$1.17K ﹤0.01% 1983

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Blue Trust Inc's PCVX Position: Q2 2026 in Review

Blue Trust Inc reduced its Vaxcyte (PCVX) stake by 0.85% in Q2 2026, selling an estimated $217 and leaving 465 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #1567.

Blue Trust Inc first reported a position in PCVX in Q3 2022 and has held it in 16 quarters since. The position peaked at $70.3K in Q2 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Blue Trust Inc held 465 shares of Vaxcyte worth $27K as of Q2 2026.
  • Blue Trust Inc sold 4 Vaxcyte shares in Q2 2026, an estimated $217.
  • Vaxcyte made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1567 holding.
  • Blue Trust Inc first reported a position in Vaxcyte in Q3 2022 and has held it in 16 quarters since.
  • Blue Trust Inc's Vaxcyte position peaked at $70.3K in Q2 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.